Search clinical trials for: Anagliptin

Total 389 results

Boehringer Ingelheim
Eli Lilly and Company

Completed

Ascertainment of EMR-based Clinical Covariates Among Patients Receiving Oral and Non-insulin Injected Hypoglycemic Therapy

Diabetes Mellitus, Type 2

United States
Boehringer Ingelheim

Completed

Efficacy and Safety of B I1356 (Linagliptin) vs. Placebo Added to Metformin Background Therapy in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Czech Republic, Finland, Greece, India, Israel, Mexico, New Zealand, Russian Federation, Sweden
Seoul National University Hospital

Unknown

Glimepiride, Alogliptin and Alogliptin+Pioglitazone Combination

Type 2 Diabetes Mellitus
Takeda

Completed

Long-term Safety Study of Alogliptin Used in Combination With Sulfonylurea or Metformin in Participants With Type 2 Diabetes in Japan

Type 2 Diabetes Mellitus
Korea University Anam Hospital

Completed

The Pharmacokinetics, Safety and Tolerability of IN-C009 in Healthy Subjects

Diabetes Mellitus

Korea, Republic of
AstraZeneca

Completed

A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD

Type 2 Diabetes Mellitus, CKD and Albuminuria

United States, Spain, Canada, Korea, Republic of, Mexico, Japan, Taiwan, Australia, South Africa
AstraZeneca
Parexel

Completed

A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-administration.

Type 2 Diabetes Mellitus

United States
Boehringer Ingelheim

Completed

BI 1356 (Linagliptin) in Combination With Metformin and a Sulphonylurea in Type 2 Diabetes

Diabetes Mellitus, Type 2

Argentina, Belgium, Canada, China, Germany, Korea, Republic of, Philippines, Russian Federation, Taiwan, Turkey, United Kingdom
Boehringer Ingelheim

Completed

Efficacy and Safety of BI 1356 (Linagliptin) Versus Placebo in Type 2 Diabetic Patients With Insufficient Glycemic Control

Diabetes Mellitus, Type 2

Croatia, India, Israel, Italy, Malaysia, Netherlands, Poland, Romania, Slovakia, Thailand, Ukraine
Emory University
Boston Medical Center; Rush University; University of Denver

Completed

Linagliptin Inpatient Trial

Type 2 Diabetes

United States
AstraZeneca

Completed

Bioequivalence Study of Fixed-dose Combinations and Coadministered Individual Tablets of Saxagliptin/Metformin-Brazil

Type 2 Diabetes Mellitus

Brazil
Beni-Suef University

Completed

Tubular Markers in Response to Saxagliptin Therapy

Diabetes Mellitus, Type 2

Egypt
Kyowa Kirin Co., Ltd.

Completed

A Phase 2 Study of OPC-262 in Patients With Type 2 Diabetes

Diabetes, Type 2

Japan
Biogen

Completed

Effect of Natalizumab on Infarct Volume in Acute Ischemic Stroke (ACTION)

Acute Ischemic Stroke

Spain, United States, Germany
Biogen

Terminated

Study of Natalizumab in Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

United States
Fayoum University
Boehringer Ingelheim

Completed

Contrast Nephropathy in Type 2 Diabetes (VCG4)

Diabetes | Microalbuminuria | Kidney Function Affection Upon Exposure to Radiocontrast

Egypt
Shanghai Zhongshan Hospital
Chinese Medical Association

Completed

Study About Effect of Saxagliptin on Circulating Endothelial Progenitor Cells and Endothelial Function in Newly Diagnosed Type 2 Diabetic Patients

Type 2 Diabetes Mellitus

China
Long Min,MD

Unknown

Dipeptidyl Peptidase 4 Inhibition Facilitate Healing of Diabetic Ulcers (DPP4i)

Diabetic Foot Ulcer

China
Boehringer Ingelheim
Eli Lilly and Company

Completed

MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin

Diabetes Mellitus, Type 2

Germany, Spain, United States, Canada, Taiwan, Korea, Republic of, Finland, Denmark, France, Japan, Philippines, Vietnam
Fourth People's Hospital of Shenyang

Completed

The Effect of Alogliptin on Pulmonary Function in Obese Patients With Type 2 Diabetes Inadequately Controlled by Metformin Monotherapy

Diabetes Mellitus, Type 2
Boehringer Ingelheim

Completed

Bioequivalence of a Linagliptin / Metformin Fixed-dose Combination (FDC) Tablet Compared With Single Linagliptin and Metformin Tablets Administered Together in Healthy Volunteers

Healthy
Boehringer Ingelheim

Completed

Bioequivalence of a 2.5 mg Linagliptin / 850 mg Metformin Fixed Dose Combination Tablet Compared With Single Linagliptin 2.5 mg and Metformin 850 mg Tablets in Healthy Volunteers

Healthy
Boehringer Ingelheim

Completed

Bioequivalence of Metformin Under Fed Conditions After Administration of Linagliptin / Metformin Fixed Dose Combination Tablet and Single Tablets

Healthy

Germany
EMS

Not yet recruiting

Efficacy and Safety of Madalena Association in the Treatment of Type II Diabetes Mellitus

Type 2 Diabetes Mellitus
University of Pisa

Completed

Effects of Dapagliflozin+Saxagliptin in Addition to Metformin v/s Saxagliptin or Dapagliflozin in Patients With DM2.

Type2 Diabetes Mellitus

Italy
Boehringer Ingelheim
Eli Lilly and Company

Completed

Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Japanese Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Japan
AstraZeneca

Completed

Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin IR Compared to Saxagliptin Monotherapy and to Metformin IR Monotherapy in Drug Naive Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control

Type 2 Diabetes Mellitus

China
JW Pharmaceutical

Active, not recruiting

Korean Observational Study to Evaluate the Efficacy and Safety of Anagliptin Switching From Other DPP4is in type2 DM (SSUG)

Type 2 Diabetes Mellitus

Korea, Republic of
Unity Health Toronto

Completed

Saxagliptin and Cardiac Structure and Function (SCARF)

Heart Failure | Diabetes Mellitus, Non-Insulin-Dependent

Canada
Boehringer Ingelheim
Eli Lilly and Company

Completed

Linagliptin as Add on to Basal Insulin in the Elderly

Diabetes Mellitus, Type 2

United States, New Zealand, Spain, Japan, Finland, Germany, Greece, Romania, South Africa, Denmark, Colombia, Poland, United Kingdom, Mexico, Australia, Belgium, Ireland
Boehringer Ingelheim
Eli Lilly and Company

Completed

Efficacy and Safety of Linagliptin in Elderly Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Australia, Canada, Denmark, Netherlands, Sweden
Takeda

Completed

A Study for Post-Marketing Surveillance of Nesina® Tablet Monotherapy or Combination Therapy in Participants With Type 2 Diabetes (T2DM) in South Korea

Type 2 Diabetes Mellitus

Korea, Republic of
Rabin Medical Center

Terminated

Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19

Glucose Metabolism Disorders | Respiratory Tract Diseases | Diabetes Mellitus, Type 2 | Diabetes Mellitus | Endocrine System Diseases | COVID 19 | Coronavirus | Metabolic Disease | Severe Acute Respiratory Syndrome Coronavirus 2 | Sars-CoV2 | Hormones | Hypoglycemic Agents | Incretins | Dipeptidyl-Peptidase IV Inhibitors and other conditions

Israel
Takeda

Completed

An Observational Study of Alogliptin Benzoate in Participants With Diabetes Mellitus Type 2

Diabetes Mellitus

Russian Federation
Assistance Publique - Hôpitaux de Paris

Completed

ACute and Chronic Effects of Saxagliptin (ACCES)

Impaired Glucose Tolerance

France
Dong Wha Pharmaceutical Co. Ltd.

Completed

A Pharmacokinetic Study of DW6013 (FDC of Linagliptin and Metformin) in Healthy Adult Volunteers in Fed Condition

Healthy Subjects

Korea, Republic of
AstraZeneca

Completed

Bioequivalence Study

Diabetes

United States
ikfe-CRO GmbH
AstraZeneca; IKFE Institute for Clinical Research and Development

Unknown

Investigation of a Switch From Insulin Therapy to a Metformin & Saxagliptin Combination in Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Germany
Boehringer Ingelheim
Eli Lilly and Company

Completed

Linagliptin Add-on to Insulin Background Therapy

Diabetes Mellitus, Type 2

China
Boehringer Ingelheim
Eli Lilly and Company

Completed

Bioequivalence of a FDC Tablet of Linagliptin/Metformin (2.5mg/1000mg) Extended Release in Healthy Subjects.

Healthy

Germany
LG Life Sciences

Completed

A Phase IIIb Study to Evaluate the Safety and Efficacy of Gemigliptin in Type 2 Diabetes Mellitus Patients With Moderate or Severe Renal Impairment(GUARD Study) (GUARD)

Type 2 DM Patients With Moderate or Severe Renal Impairment

Korea, Republic of
Beijing Chao Yang Hospital

Unknown

Evaluate the Effect of Saxagliptin on Gut Microbiota in Patients With Newly Diagnosed Type 2 Diabetes

Obesity | Type 2 Diabetes
Ministry of Public Health, Argentina
Aix Marseille Université; Instituto de Biología y Medicina Experimental, IBYME...

Unknown

Effect of Linagliptin on TRL Metabolism

Type 2 Diabetes

Argentina
Boehringer Ingelheim

Completed

Bioequivalence of a 2.5 mg Linagliptin / 500 mg Metformin Fixed Dose Combination Tablet Compared With Single Linagliptin 2.5 mg and Metformin 500 mg Tablets Administered Together in Healthy Volunteers

Healthy
Universidad de Guanajuato
Hospital Regional de Alta Especialidad del Bajio

Completed

Effect of Linagliptin + Metformin vs Metformin Alone in Patients With Prediabetes (PRELLIM)

Insulin Resistance | Prediabetic State

Mexico
Boehringer Ingelheim

Completed

Pharmacokinetics and Pharmacodynamics Trial With Linagliptin (BI 1356) 5mg in African American Type 2 Diabetic Patients

Diabetes Mellitus, Type 2

United States
Takeda

Completed

Alogliptin/Pioglitazone (Liovel) Combination Tablets Survey on Long-term Use in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Japan
Boehringer Ingelheim
Eli Lilly and Company

Completed

Bioequivalence of a FDC Tablet of Linagliptin/Metformin (5mg/1000mg) Extended Release in Healthy Subjects

Healthy

Germany
Boehringer Ingelheim
Eli Lilly and Company

Completed

Bioequivalence of a FDC Tablet of Linagliptin/Metformin (2.5mg/750mg) Extended Release in Healthy Subjects

Healthy

Germany
Boehringer Ingelheim

Completed

The Effect of Linagliptin (BI 1356) on 24h-glucose Control and Various Biomarkers in Type 2 Diabetic Patients

Diabetes Mellitus, Type 2

Germany

3

Subscribe